#United States #Houston #Diakonos Oncology #DOC1021 #ASCO 2026

Diakonos Oncology's Major Updates at ASCO 2026

On June 5, 2026, Diakonos Oncology Corp., a leading clinical-stage biotechnology company, unveiled exciting new data at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The company showcased the updated survival data for its lead immunotherapy product, DOC1021 (dubodencel), specifically designed for challenging cancers like glioblastoma and melanoma.

Promising Survival Rates for Glioblastoma

In the presentation, Diakonos reported significant findings from a pooled analysis of its Phase 1 study and an expanded access protocol involving DOC1021 for glioblastoma (GBM). The results highlighted a remarkable 90% overall survival rate at 12 months among newly diagnosed patients, primarily from an MGMT-unmethylated population. This group generally experiences poorer outcomes and limited treatment options.

Key Findings from the GBM Studies

• - The average survival time for newly diagnosed patients was reported to be 18.5 months, ranging from 8.7 to 38.4 months.
• - For recurrent GBM patients, survival spanned 10.2 to 22 months after secondary surgery.
• - The study maintained a favorable safety profile, with no dose-limiting toxicities observed.
• - Immune analysis indicated consistent activation of memory T cells, reinforcing the sustained immune response offered by DOC1021.

In light of these results, Diakonos is currently enrolling patients in a randomized Phase 2 trial across over 15 clinical sites, comparing DOC1021 plus standard care against standard care alone for newly diagnosed GBM patients.

Expert Insights

Dr. Jay-Jiguang Zhu from UTHealth Houston emphasized the importance of these findings, particularly noting the favorable survival outcomes in what is traditionally a more challenging patient subgroup. He affirmed that the ongoing Phase 2 study will be crucial in evaluating both the effectiveness and safety of DOC1021 for GBM treatment.

Launch of Melanoma Study

In addition to the glioblastoma data, Diakonos announced the commencement of a new Phase 1/2 clinical study, dubbed DOC-RM, focused on refractory melanoma. This study is particularly significant given the limited therapeutic options available for patients who have exhausted anti-PD-1 treatments.

Details about the Melanoma Study

• - The clinical trial aims to evaluate DOC1021 in patients with melanoma that is either unresectable or metastatic.
• - The study will incorporate a safety cohort followed by an expansion phase to assess tumor responses after receiving DOC1021 in conjunction with pegylated interferon.
• - Initial preclinical findings supporting the trial demonstrated improved tumor responses in models of melanoma, indicating potential positive outcomes for patients facing PD-1 refractory disease.

Principal Investigator Dr. Alexandra Haugh from Massachusetts General Hospital expressed enthusiasm for exploring this novel immunotherapy approach, as DOC1021 uses an individualized dendritic cell-based strategy that presents a variety of patient-specific tumor antigens without extensive pre-treatment requirements.

About DOC1021

DOC1021 is a pioneering approach in dendritic cell therapy, utilizing patient-derived tumor lysates and amplified mRNA. This unique double-loading strategy mimics viral infection, creating a potent immune response capable of targeting the complete cancer antigen pool, thus mitigating the need for high-dose chemotherapy. Designed for outpatient administration, the treatment offers broader access to patients via community cancer centers.

Current Clinical Trials

Diakonos is actively conducting three clinical trials evaluating DOC1021 for various cancers, including a Phase 1 study for pancreatic cancer and a Phase 2 study for glioblastoma, alongside the newly initiated melanoma trial. The FDA has granted Fast Track designation to DOC1021 for treating pancreatic cancer, GBM, and unresectable or metastatic melanoma, reflecting a vital need for innovative treatment options.

Conclusion

The advancements shared by Diakonos Oncology at ASCO 2026 not only underline the company's commitment to improving survival rates for patients with aggressive cancers but also highlight the ongoing potential of immunotherapy as a promising frontier in oncology.